Clinical Trials Directory

Trials / Completed

CompletedNCT04827251

Effects of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease

Evaluation of the Effect of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
29 (actual)
Sponsor
University of Sao Paulo · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Discovered thousands of years ago, coffee is among the most consumed beverages in the world. The relationship between coffee and cardiovascular risk, more specifically coronary artery disease, is controversial. Platelet aggregation and its relationship with coffee is also controversial. The investigators propose this study to evaluate the relationship between coffee and platelet aggregability in patients with coronary artery disease.

Detailed description

30 patients with coronary artery disease (proven by previous coronary angiography) will be selected at the Heart Institute (InCor USP) for the study. Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, one group will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days and another group will start with decaffeinated coffee followed by caffeinated. All participants will receive "Nespresso" coffee maker "Essenza" model. The coffee "Nespresso blend voluto" will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over). The investigators will evaluate platelet aggregation by Multiplate® (ASPI, ADP and arachidonic acid) and by optical aggregometry (ADP and arachidonic acid).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCoffeeParticipants will receive "Nespresso" coffee maker "Essenza" model. The coffee "Nespresso blend voluto" will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over).

Timeline

Start date
2022-09-01
Primary completion
2024-11-25
Completion
2024-11-25
First posted
2021-04-01
Last updated
2025-02-13

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT04827251. Inclusion in this directory is not an endorsement.